## Abstract An antiserum was raised in rabbits by immunization with a human tumor cell line, T‐24, derived from transitional cell carcinoma (TCC) of the urinary bladder. The specificity of the IgG fraction was assessed by antibody‐dependent cellular cytotoxicity (ADCC), using purified blood lymphoc
Production and characterization of xenogeneic antisera to tumor-associated antigen(s)
✍ Scribed by Rishab K. Gupta; Dr. Hulbert K. B. Silver; Donald L. Morton
- Publisher
- John Wiley and Sons
- Year
- 1980
- Tongue
- English
- Weight
- 836 KB
- Volume
- 13
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Tumor‐associated antigen(s) from a specimen of human malignant melanoma and from spent culture medium of a melanoma cell line were extracted and purified. The incidence of antibody activity to these antigens, in sera from cancer patients with neoplasms of various histologic types, was higher (65–83%) than normal donors' (19–25%) by the complement fixation assay. These purified antigens were then used to raise antisera in rabbits and sheep. After absorption with various human normal tissues, these antisera reacted against melanoma, sarcoma, and carcinoma extracts, but not against human normal liver, skin, or muscle extracts. However, the antisera showed reactivity against a human fetal homogenate. Results indicate that the xenogeneic antisera contained antibodies to fetal antigens and to tumor‐associated antigen(s). Xenogeneic antisera could be used to purify tumor‐associated antigens and oncofetal antigen(s) from crude extracts by affinity chromatography.
📜 SIMILAR VOLUMES
## Abstract Cytotoxic antibodies against glioblastoma‐associated antigen(s) have been sought for in glioma patient sera. Complement‐dependent cytotoxicity (CDC) and antibody‐dependent cell‐mediated cytotoxicity (ADCC) assays were used to test sera from 80 patients using ^51^Cr labelled target cells
## Abstract Using allogeneic antibody, we previously described a highmolecular‐weight glycoprotein in the urine of 68% of melanoma patients. This glycoprotein has been termed urinarytumor‐associated antigen (U‐TAA). A murine monoclonal antibody (MAb) specific for U‐TAA (AD1‐40F4) has been developed